肝がん治療薬の市場規模、シェア、動向分析レポート：治療別、タイプ別、流通チャネル別、地域別、2025年～2030年のセグメント動向

肝がん治療薬市場の成長と動向

Grand View Research, Inc.の最新レポートによると、肝がん治療薬の世界市場規模は2030年までに98億1,000万米ドルに達すると予測されています。

同市場は2025～2030年にかけてCAGR 17.9％で成長すると予測されています。肝臓がん市場の成長は、新薬の利用可能性、強力なパイプラインの存在、社会的認知度の上昇などの要因によって大きく左右されます。肝臓がん患者の裾野が広がっている背景には、不健康なライフスタイルや高齢者の増加があります。これは肝がん治療薬市場に有利に働いています。ネクサバールに不耐容の患者を対象としたセカンドライン治療の開発は、肝がん領域に大きな影響を与えると推定されます。

肝がんは世界で5番目に罹患率の高いがんであり、がんによる死亡者数の9.0%を占めています。2012年には782,451人が新たに肝がんと診断され、74万5,533人が肝がんで死亡したと報告されています。原発性肝がんは、その極めて侵攻的な性質と生存率の低さから、依然として重要な公衆衛生上の問題です。肝細胞がんは原発性肝がんの大部分（75～90％）を占めます。肝炎感染や肝硬変を含む肝がんの注目すべき多くの病因因子は修正可能であり、生活習慣の改善や肝炎の予防接種などの予防戦略によって、その発生率や死亡率を低下させる強い展望を示しています。

肝がん治療薬市場レポートハイライト

• 標的治療セグメントは、がん細胞の増殖と拡散に関与する特定の分子や経路を標的とする精度の高さにより、2024年には53.1%の最大市場収益シェアを占めました。
• 肝細胞がん（HCC）は2024年の収益シェア38.2%で肝がん治療薬市場を独占しました。肝細胞がんは原発性肝がんの中で最も一般的なタイプです。
• 病院薬局が2024年の収益シェア45.7%で肝がん治療薬市場を独占.
• 北米の肝がん治療薬市場は、2024年に38.7%の売上シェアを占めました。

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 肝がん治療薬市場の変数、動向、範囲

• 市場系統の展望
• 市場力学
  • 市場促進要因分析
  • 市場抑制要因分析
• ビジネス環境分析
  • 産業分析-ポーターのファイブフォース分析
  • PESTLE分析
  • パイプライン分析

第4章 肝がん治療薬市場：治療別ビジネス分析

• 治療別市場シェア、2024年と2030年
• 治療セグメントダッシュボード
• 市場規模と予測と動向分析、治療別、2018～2030年
• 標的治療
• 免疫治療
• 化学治療
• その他

第5章 肝がん治療薬市場：タイプ別ビジネス分析

• タイプ別市場シェア、2024年と2030年
• タイプセグメントダッシュボード
• 市場規模と予測と動向分析、タイプ別、2018～2030年
• 肝細胞がん
• 胆管がん
• 肝芽腫
• その他

第6章 肝がん治療薬市場：流通チャネル別ビジネス分析

• 流通チャネル別市場シェア、2024年と2030年
• 流通チャネルセグメントダッシュボード
• 市場規模と予測と動向分析、流通チャネル別、2018～2030年
• 病院薬局
• 小売薬局
• オンライン薬局

第7章 肝がん治療薬市場：地域別、推定・動向分析

• 地域別市場シェア分析、2024年と2030年
• 地域別市場ダッシュボード
• 市場規模、予測動向分析、2018～2030年
• 北米
  • 国別、2018～2030年
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • 国別、2018～2030年
  • ドイツ
  • 英国
  • フランス
  • イタリア
  • スペイン
  • デンマーク
  • スウェーデン
  • ノルウェー
• アジア太平洋
  • 国別、2018～2030年
  • 日本
  • 中国
  • インド
  • オーストラリア
  • 韓国
  • タイ
• ラテンアメリカ
  • 国別、2018～2030年
  • ブラジル
  • アルゼンチン
• 中東・アフリカ
  • 国別、2018～2030年
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦
  • クウェート

第8章 競合情勢

• 参加者概要
• 企業の市況分析
• 企業分類
• 戦略マッピング
• 企業プロファイル/上場企業
  • Exelixis, Inc.
  • Merck KGaA
  • Eisai Co., Ltd.
  • Bristol-Myers Squibb Company
  • Thermo Fisher Scientific Inc.
  • Pfizer Inc.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd
  • Novartis AG
  • Bayer AG

List of Tables

• Table 1 List Of Secondary Sources
• Table 2 List Of Abbreviations
• Table 3 Global Liver Cancer Drug Market, By Region, 2018 - 2030 (USD Million)
• Table 4 Global Liver Cancer Drug Market, By Therapy, 2018 - 2030 (USD Million)
• Table 5 Global Liver Cancer Drug Market, By Type, 2018 - 2030 (USD Million)
• Table 6 Global Liver Cancer Drug Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 7 North America Liver Cancer Drug Market, By Country, 2018 - 2030 (USD Million)
• Table 8 North America Liver Cancer Drug Market, By Therapy, 2018 - 2030 (USD Million)
• Table 9 North America Liver Cancer Drug Market, By Type, 2018 - 2030 (USD Million)
• Table 10 North America Liver Cancer Drug Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 11 U.S. Liver Cancer Drug Market, By Therapy, 2018 - 2030 (USD Million)
• Table 12 U.S. Liver Cancer Drug Market, By Type, 2018 - 2030 (USD Million)
• Table 13 U.S. Liver Cancer Drug Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 14 Canada Liver Cancer Drug Market, By Therapy, 2018 - 2030 (USD Million)
• Table 15 Canada Liver Cancer Drug Market, By Type, 2018 - 2030 (USD Million)
• Table 16 Canada Liver Cancer Drug Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 17 Mexico Liver Cancer Drug Market, By Therapy, 2018 - 2030 (USD Million)
• Table 18 Mexico Liver Cancer Drug Market, By Type, 2018 - 2030 (USD Million)
• Table 19 Mexico Liver Cancer Drug Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 20 Europe Liver Cancer Drug Market, By Country, 2018 - 2030 (USD Million)
• Table 21 Europe Liver Cancer Drug Market, By Therapy, 2018 - 2030 (USD Million)
• Table 22 Europe Liver Cancer Drug Market, By Type, 2018 - 2030 (USD Million)
• Table 23 Europe Liver Cancer Drug Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 24 Germany Liver Cancer Drug Market, By Therapy, 2018 - 2030 (USD Million)
• Table 25 Germany Liver Cancer Drug Market, By Type, 2018 - 2030 (USD Million)
• Table 26 Germany Liver Cancer Drug Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 27 UK Liver Cancer Drug Market, By Therapy, 2018 - 2030 (USD Million)
• Table 28 UK Liver Cancer Drug Market, By Type, 2018 - 2030 (USD Million)
• Table 29 UK Liver Cancer Drug Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 30 France Liver Cancer Drug Market, By Therapy, 2018 - 2030 (USD Million)
• Table 31 France Liver Cancer Drug Market, By Type, 2018 - 2030 (USD Million)
• Table 32 France Liver Cancer Drug Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 33 Italy Liver Cancer Drug Market, By Therapy, 2018 - 2030 (USD Million)
• Table 34 Italy Liver Cancer Drug Market, By Type, 2018 - 2030 (USD Million)
• Table 35 Italy Liver Cancer Drug Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 36 Spain Liver Cancer Drug Market, By Therapy, 2018 - 2030 (USD Million)
• Table 37 Spain Liver Cancer Drug Market, By Type, 2018 - 2030 (USD Million)
• Table 38 Spain Liver Cancer Drug Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 39 Denmark Liver Cancer Drug Market, By Therapy, 2018 - 2030 (USD Million)
• Table 40 Denmark Liver Cancer Drug Market, By Type, 2018 - 2030 (USD Million)
• Table 41 Denmark Liver Cancer Drug Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 42 Sweden Liver Cancer Drug Market, By Therapy, 2018 - 2030 (USD Million)
• Table 43 Sweden Liver Cancer Drug Market, By Type, 2018 - 2030 (USD Million)
• Table 44 Sweden Liver Cancer Drug Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 45 Norway Liver Cancer Drug Market, By Therapy, 2018 - 2030 (USD Million)
• Table 46 Norway Liver Cancer Drug Market, By Type, 2018 - 2030 (USD Million)
• Table 47 Norway Liver Cancer Drug Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 48 Asia Pacific Liver Cancer Drug Market, By Country, 2018 - 2030 (USD Million)
• Table 49 Asia Pacific Liver Cancer Drug Market, By Therapy, 2018 - 2030 (USD Million)
• Table 50 Asia Pacific Liver Cancer Drug Market, By Type, 2018 - 2030 (USD Million)
• Table 51 Asia Pacific Liver Cancer Drug Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 52 Japan Liver Cancer Drug Market, By Therapy, 2018 - 2030 (USD Million)
• Table 53 Japan Liver Cancer Drug Market, By Type, 2018 - 2030 (USD Million)
• Table 54 Japan Liver Cancer Drug Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 55 China Liver Cancer Drug Market, By Therapy, 2018 - 2030 (USD Million)
• Table 56 China Liver Cancer Drug Market, By Type, 2018 - 2030 (USD Million)
• Table 57 China Liver Cancer Drug Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 58 India Liver Cancer Drug Market, By Therapy, 2018 - 2030 (USD Million)
• Table 59 India Liver Cancer Drug Market, By Type, 2018 - 2030 (USD Million)
• Table 60 India Liver Cancer Drug Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 61 Australia Liver Cancer Drug Market, By Therapy, 2018 - 2030 (USD Million)
• Table 62 Australia Liver Cancer Drug Market, By Type, 2018 - 2030 (USD Million)
• Table 63 Australia Liver Cancer Drug Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 64 South Korea Liver Cancer Drug Market, By Therapy, 2018 - 2030 (USD Million)
• Table 65 South Korea Liver Cancer Drug Market, By Type, 2018 - 2030 (USD Million)
• Table 66 South Korea Liver Cancer Drug Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 67 Thailand Liver Cancer Drug Market, By Therapy, 2018 - 2030 (USD Million)
• Table 68 Thailand Liver Cancer Drug Market, By Type, 2018 - 2030 (USD Million)
• Table 69 Thailand Liver Cancer Drug Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 70 Latin America Liver Cancer Drug Market, By Country, 2018 - 2030 (USD Million)
• Table 71 Latin America Liver Cancer Drug Market, By Therapy, 2018 - 2030 (USD Million)
• Table 72 Latin America Liver Cancer Drug Market, By Type, 2018 - 2030 (USD Million)
• Table 73 Latin America Liver Cancer Drug Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 74 Brazil Liver Cancer Drug Market, By Therapy, 2018 - 2030 (USD Million)
• Table 75 Brazil Liver Cancer Drug Market, By Type, 2018 - 2030 (USD Million)
• Table 76 Brazil Liver Cancer Drug Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 77 Argentina Liver Cancer Drug Market, By Therapy, 2018 - 2030 (USD Million)
• Table 78 Argentina Liver Cancer Drug Market, By Type, 2018 - 2030 (USD Million)
• Table 79 Argentina Liver Cancer Drug Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 80 Middle East & Africa Liver Cancer Drug Market, By Country, 2018 - 2030 (USD Million)
• Table 81 Middle East & Africa Liver Cancer Drug Market, By Therapy, 2018 - 2030 (USD Million)
• Table 82 Middle East & Africa Liver Cancer Drug Market, By Type, 2018 - 2030 (USD Million)
• Table 83 Middle East & Africa Liver Cancer Drug Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 84 South Africa Liver Cancer Drug Market, By Therapy, 2018 - 2030 (USD Million)
• Table 85 South Africa Liver Cancer Drug Market, By Type, 2018 - 2030 (USD Million)
• Table 86 South Africa Liver Cancer Drug Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 87 Saudi Arabia Liver Cancer Drug Market, By Therapy, 2018 - 2030 (USD Million)
• Table 88 Saudi Arabia Liver Cancer Drug Market, By Type, 2018 - 2030 (USD Million)
• Table 89 Saudi Arabia Liver Cancer Drug Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 90 UAE Liver Cancer Drug Market, By Therapy, 2018 - 2030 (USD Million)
• Table 91 UAE Liver Cancer Drug Market, By Type, 2018 - 2030 (USD Million)
• Table 92 UAE Liver Cancer Drug Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 93 Kuwait Liver Cancer Drug Market, By Therapy, 2018 - 2030 (USD Million)
• Table 94 Kuwait Liver Cancer Drug Market, By Type, 2018 - 2030 (USD Million)
• Table 95 Kuwait Liver Cancer Drug Market, By Distribution Channel, 2018 - 2030 (USD Million)

List of Figures

• Fig. 1 Liver Cancer Drug Market Segmentation
• Fig. 2 Market Research Process
• Fig. 3 Data Triangulation Techniques
• Fig. 4 Primary Research Pattern
• Fig. 5 Market Research Approaches
• Fig. 6 Value-Chain-Based Sizing & Forecasting
• Fig. 7 Market Formulation & Validation
• Fig. 8 Market Snapshot
• Fig. 9 Therapy and Type Outlook (USD Million)
• Fig. 10 Distribution Channel Outlook (USD Million)
• Fig. 11 Competitive Landscape
• Fig. 12 Liver Cancer Drug Market Dynamics
• Fig. 13 Liver Cancer Drug Market: Porter's Five Forces Analysis
• Fig. 14 Liver Cancer Drug Market: PESTLE Analysis
• Fig. 15 Liver Cancer Drug Market: Therapy Segment Dashboard
• Fig. 16 Liver Cancer Drug Market: Therapy Market Share Analysis, 2024 & 2030
• Fig. 17 Targeted Therapy Market, 2018 - 2030 (USD Million)
• Fig. 18 Immunotherapy Market, 2018 - 2030 (USD Million)
• Fig. 19 Chemotherapy Market, 2018 - 2030 (USD Million)
• Fig. 20 Others Market, 2018 - 2030 (USD Million)
• Fig. 21 Liver Cancer Drug Market: Type Segment Dashboard
• Fig. 22 Liver Cancer Drug Market: Type Market Share Analysis, 2024 & 2030
• Fig. 23 Hepatocellular Carcinoma Market, 2018 - 2030 (USD Million)
• Fig. 24 Cholangio Carcinoma Market, 2018 - 2030 (USD Million)
• Fig. 25 Hepatoblastoma Market, 2018 - 2030 (USD Million)
• Fig. 26 Others Market, 2018 - 2030 (USD Million)
• Fig. 27 Liver Cancer Drug Market: Distribution Channel Segment Dashboard
• Fig. 28 Liver Cancer Drug Market: Distribution Channel Market Share Analysis, 2024 & 2030
• Fig. 29 Hospital Pharmacies Market, 2018 - 2030 (USD Million)
• Fig. 30 Retail Pharmacies Market, 2018 - 2030 (USD Million)
• Fig. 31 Online Pharmacies Market, 2018 - 2030 (USD Million)
• Fig. 32 Liver Cancer Drug Market Revenue, By Region
• Fig. 33 Regional Marketplace: Key Takeaways
• Fig. 34 Regional Marketplace: Key Takeaways
• Fig. 35 North America Liver Cancer Drug Market, 2018 - 2030 (USD Million)
• Fig. 36 U.S. Country Dynamics
• Fig. 37 U.S. Liver Cancer Drug Market, 2018 - 2030 (USD Million)
• Fig. 38 Canada Country Dynamics
• Fig. 39 Canada Liver Cancer Drug Market, 2018 - 2030 (USD Million)
• Fig. 40 Mexico Country Dynamics
• Fig. 41 Mexico Liver Cancer Drug Market, 2018 - 2030 (USD Million)
• Fig. 42 Europe Liver Cancer Drug Market, 2018 - 2030 (USD Million)
• Fig. 43 Germany Country Dynamics
• Fig. 44 Germany Liver Cancer Drug Market, 2018 - 2030 (USD Million)
• Fig. 45 UK Country Dynamics
• Fig. 46 UK Liver Cancer Drug Market, 2018 - 2030 (USD Million)
• Fig. 47 France Country Dynamics
• Fig. 48 France Liver Cancer Drug Market, 2018 - 2030 (USD Million)
• Fig. 49 Italy Country Dynamics
• Fig. 50 Italy Liver Cancer Drug Market, 2018 - 2030 (USD Million)
• Fig. 51 Spain Country Dynamics
• Fig. 52 Spain Liver Cancer Drug Market, 2018 - 2030 (USD Million)
• Fig. 53 Norway Country Dynamics
• Fig. 54 Norway Liver Cancer Drug Market, 2018 - 2030 (USD Million)
• Fig. 55 Sweden Country Dynamics
• Fig. 56 Sweden Liver Cancer Drug Market, 2018 - 2030 (USD Million)
• Fig. 57 Denmark Country Dynamics
• Fig. 58 Denmark Liver Cancer Drug Market, 2018 - 2030 (USD Million)
• Fig. 59 Asia Pacific Liver Cancer Drug Market, 2018 - 2030 (USD Million)
• Fig. 60 Japan Country Dynamics
• Fig. 61 Japan Liver Cancer Drug Market, 2018 - 2030 (USD Million)
• Fig. 62 China Country Dynamics
• Fig. 63 China Liver Cancer Drug Market, 2018 - 2030 (USD Million)
• Fig. 64 India Country Dynamics
• Fig. 65 India Liver Cancer Drug Market, 2018 - 2030 (USD Million)
• Fig. 66 Australia Country Dynamics
• Fig. 67 Australia Liver Cancer Drug Market, 2018 - 2030 (USD Million)
• Fig. 68 South Korea Country Dynamics
• Fig. 69 South Korea Liver Cancer Drug Market, 2018 - 2030 (USD Million)
• Fig. 70 Thailand Country Dynamics
• Fig. 71 Thailand Liver Cancer Drug Market, 2018 - 2030 (USD Million)
• Fig. 72 Latin America Liver Cancer Drug Market, 2018 - 2030 (USD Million)
• Fig. 73 Brazil Country Dynamics
• Fig. 74 Brazil Liver Cancer Drug Market, 2018 - 2030 (USD Million)
• Fig. 75 Argentina Country Dynamics
• Fig. 76 Argentina Liver Cancer Drug Market, 2018 - 2030 (USD Million)
• Fig. 77 MEA Liver Cancer Drug Market, 2018 - 2030 (USD Million)
• Fig. 78 South Africa Country Dynamics
• Fig. 79 South Africa Liver Cancer Drug Market, 2018 - 2030 (USD Million)
• Fig. 80 Saudi Arabia Country Dynamics
• Fig. 81 Saudi Arabia Liver Cancer Drug Market, 2018 - 2030 (USD Million)
• Fig. 82 UAE Country Dynamics
• Fig. 83 UAE Liver Cancer Drug Market, 2018 - 2030 (USD Million)
• Fig. 84 Kuwait Country Dynamics
• Fig. 85 Kuwait Liver Cancer Drug Market, 2018 - 2030 (USD Million)
• Fig. 86 Company Categorization
• Fig. 87 Company Market Position Analysis
• Fig. 88 Strategic Framework

Liver Cancer Drug Market Growth & Trends:

The global liver cancer drug market size is anticipated to reach USD 9.81 billion by 2030, according to a new report by Grand View Research, Inc. The market is projected to grow at a CAGR of 17.9% from 2025 to 2030. The growth of liver cancer market is largely driven by factors such as availability of novel drugs, presence of strong pipeline, and rising public awareness. Widening base of liver cancer patients can be attributed to unhealthy lifestyles and growing geriatric population. This, in turn, is working in favor of the liver cancer therapeutics market. Therapeutic development in second-line setting for Nexavar-intolerant patients is estimated to have a major impact in the HCC space.

Liver cancer is the fifth most prevalent cancer worldwide and accounts for 9.0% of all cancer deaths. In 2012, 782,451 new cases of liver cancer were diagnosed, and 745,533 deaths were reported due to liver cancer. Primary liver cancer remains an important public health issue due to its extremely aggressive nature and poor survival rate. Hepatocellular carcinomas (HCCs) represents the majority (75-90%) of primary liver cancers. A noteworthy number of etiological factors of liver cancer, including hepatitis infection and cirrhosis, can be modified and present a strong prospect to reduce its incidence and mortality by preventive strategies such as lifestyle modification and hepatitis immunization.

Liver Cancer Drug Market Report Highlights:

• The targeted therapy segment held the largest market revenue share of 53.1% in 2024 due to its precision in targeting specific molecules or pathways involved in the growth and spread of cancer cells.
• Hepatocellular Carcinoma (HCC) dominated the liver cancer drug market with a 38.2% revenue share in 2024. HCC Is the most common type of primary liver cancer.
• Hospital pharmacy dominated the liver cancer drug market with a revenue share of 45.7% in 2024.
• North America liver cancer drug market held a revenue share of 38.7% in 2024.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Therapy
  • 1.2.2. Type
  • 1.2.3. Distribution Channel
• 1.3. Estimates and Forecast Timeline
• 1.4. Research Methodology
• 1.5. Information Procurement
  • 1.5.1. Purchased Database
  • 1.5.2. GVR's Internal Database
  • 1.5.3. Secondary Sources
  • 1.5.4. Primary Research
• 1.6. Information Analysis
  • 1.6.1. Data Analysis Models
• 1.7. Market Formulation & Data Visualization
• 1.8. Model Details
  • 1.8.1. Commodity Flow Analysis
• 1.9. List of Secondary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Snapshot
• 2.2. Segment Snapshot
• 2.3. Competitive Landscape Snapshot

Chapter 3. Liver Cancer Drug Market Variables, Trends, & Scope

• 3.1. Market Lineage Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
  • 3.2.2. Market Restraint Analysis
• 3.3. Business Environment Analysis
  • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
    • 3.3.1.1. Supplier Power
    • 3.3.1.2. Buyer Power
    • 3.3.1.3. Substitution Threat
    • 3.3.1.4. Threat of New Entrants
    • 3.3.1.5. Competitive Rivalry
  • 3.3.2. PESTLE Analysis
  • 3.3.3. Pipeline Analysis

Chapter 4. Liver Cancer Drug Market: Therapy Business Analysis

• 4.1. Therapy Market Share, 2024 & 2030
• 4.2. Therapy Segment Dashboard
• 4.3. Market Size & Forecasts and Trend Analysis, by Therapy, 2018 to 2030 (USD Million)
• 4.4. Targeted Therapy
  • 4.4.1. Targeted Therapy Market, 2018 - 2030 (USD Million)
• 4.5. Immunotherapy
  • 4.5.1. Immunotherapy Market, 2018 - 2030 (USD Million)
• 4.6. Chemotherapy
  • 4.6.1. Chemotherapy Market, 2018 - 2030 (USD Million)
• 4.7. Others
  • 4.7.1. Others Market, 2018 - 2030 (USD Million)

Chapter 5. Liver Cancer Drug Market: Type Business Analysis

• 5.1. Type Market Share, 2024 & 2030
• 5.2. Type Segment Dashboard
• 5.3. Market Size & Forecasts and Trend Analysis, by Type, 2018 to 2030 (USD Million)
• 5.4. Hepatocellular Carcinoma
  • 5.4.1. Hepatocellular Carcinoma Market, 2018 - 2030 (USD Million)
• 5.5. Cholangio Carcinoma
  • 5.5.1. Cholangio Carcinoma Market, 2018 - 2030 (USD Million)
• 5.6. Hepatoblastoma
  • 5.6.1. Hepatoblastoma Market, 2018 - 2030 (USD Million)
• 5.7. Others
  • 5.7.1. Others Market, 2018 - 2030 (USD Million)

Chapter 6. Liver Cancer Drug Market: Distribution Channel Business Analysis

• 6.1. Distribution Channel Market Share, 2024 & 2030
• 6.2. Distribution Channel Segment Dashboard
• 6.3. Market Size & Forecasts and Trend Analysis, by Distribution Channel, 2018 to 2030 (USD Million)
• 6.4. Hospital Pharmacies
  • 6.4.1. Hospital Pharmacies Market, 2018 - 2030 (USD Million)
• 6.5. Retail Pharmacies
  • 6.5.1. Retail Pharmacies Market, 2018 - 2030 (USD Million)
• 6.6. Online Pharmacies
  • 6.6.1. Online Pharmacies Market, 2018 - 2030 (USD Million)

Chapter 7. Liver Cancer Drug Market: Regional Estimates & Trend Analysis

• 7.1. Regional Market Share Analysis, 2024 & 2030
• 7.2. Regional Market Dashboard
• 7.3. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
• 7.4. North America
  • 7.4.1. North America Liver Cancer Drug Market Estimates and Forecasts, By Country, 2018 - 2030 (USD Million)
  • 7.4.2. U.S.
    • 7.4.2.1. Key Country Dynamics
    • 7.4.2.2. Regulatory Framework
    • 7.4.2.3. Competitive Insights
    • 7.4.2.4. U.S. Liver Cancer Drug Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.4.3. Canada
    • 7.4.3.1. Key Country Dynamics
    • 7.4.3.2. Regulatory Framework
    • 7.4.3.3. Competitive Insights
    • 7.4.3.4. Canada Liver Cancer Drug Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.4.4. Mexico
    • 7.4.4.1. Key Country Dynamics
    • 7.4.4.2. Regulatory Framework
    • 7.4.4.3. Competitive Insights
    • 7.4.4.4. Mexico Liver Cancer Drug Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 7.5. Europe
  • 7.5.1. Europe Liver Cancer Drug Market Estimates and Forecasts, By Country, 2018 - 2030 (USD Million)
  • 7.5.2. Germany
    • 7.5.2.1. Key Country Dynamics
    • 7.5.2.2. Regulatory Framework
    • 7.5.2.3. Competitive Insights
    • 7.5.2.4. Germany Liver Cancer Drug Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5.3. UK
    • 7.5.3.1. Key Country Dynamics
    • 7.5.3.2. Regulatory Framework
    • 7.5.3.3. Competitive Insights
    • 7.5.3.4. UK Liver Cancer Drug Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5.4. France
    • 7.5.4.1. Key Country Dynamics
    • 7.5.4.2. Regulatory Framework
    • 7.5.4.3. Competitive Insights
    • 7.5.4.4. France Liver Cancer Drug Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5.5. Italy
    • 7.5.5.1. Key Country Dynamics
    • 7.5.5.2. Regulatory Framework
    • 7.5.5.3. Competitive Insights
    • 7.5.5.4. Italy Liver Cancer Drug Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5.6. Spain
    • 7.5.6.1. Key Country Dynamics
    • 7.5.6.2. Regulatory Framework
    • 7.5.6.3. Competitive Insights
    • 7.5.6.4. Spain Liver Cancer Drug Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5.7. Denmark
    • 7.5.7.1. Key Country Dynamics
    • 7.5.7.2. Regulatory Framework
    • 7.5.7.3. Competitive Insights
    • 7.5.7.4. Denmark Liver Cancer Drug Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5.8. Sweden
    • 7.5.8.1. Key Country Dynamics
    • 7.5.8.2. Regulatory Framework
    • 7.5.8.3. Competitive Insights
    • 7.5.8.4. Sweden Liver Cancer Drug Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5.9. Norway
    • 7.5.9.1. Key Country Dynamics
    • 7.5.9.2. Regulatory Framework
    • 7.5.9.3. Competitive Insights
    • 7.5.9.4. Norway Liver Cancer Drug Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 7.6. Asia Pacific
  • 7.6.1. Asia Pacific Liver Cancer Drug Market Estimates and Forecasts, By Country, 2018 - 2030 (USD Million)
  • 7.6.2. Japan
    • 7.6.2.1. Key Country Dynamics
    • 7.6.2.2. Regulatory Framework
    • 7.6.2.3. Competitive Insights
    • 7.6.2.4. Japan Liver Cancer Drug Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.6.3. China
    • 7.6.3.1. Key Country Dynamics
    • 7.6.3.2. Regulatory Framework
    • 7.6.3.3. Competitive Insights
    • 7.6.3.4. China Liver Cancer Drug Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.6.4. India
    • 7.6.4.1. Key Country Dynamics
    • 7.6.4.2. Regulatory Framework
    • 7.6.4.3. Competitive Insights
    • 7.6.4.4. India Liver Cancer Drug Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.6.5. Australia
    • 7.6.5.1. Key Country Dynamics
    • 7.6.5.2. Regulatory Framework
    • 7.6.5.3. Competitive Insights
    • 7.6.5.4. Australia Liver Cancer Drug Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.6.6. South Korea
    • 7.6.6.1. Key Country Dynamics
    • 7.6.6.2. Regulatory Framework
    • 7.6.6.3. Competitive Insights
    • 7.6.6.4. South Korea Liver Cancer Drug Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.6.7. Thailand
    • 7.6.7.1. Key Country Dynamics
    • 7.6.7.2. Regulatory Framework
    • 7.6.7.3. Competitive Insights
    • 7.6.7.4. Thailand Liver Cancer Drug Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 7.7. Latin America
  • 7.7.1. Latin America Liver Cancer Drug Market Estimates and Forecasts, By Country, 2018 - 2030 (USD Million)
  • 7.7.2. Brazil
    • 7.7.2.1. Key Country Dynamics
    • 7.7.2.2. Regulatory Framework
    • 7.7.2.3. Competitive Insights
    • 7.7.2.4. Brazil Liver Cancer Drug Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.7.3. Argentina
    • 7.7.3.1. Key Country Dynamics
    • 7.7.3.2. Regulatory Framework
    • 7.7.3.3. Competitive Insights
    • 7.7.3.4. Argentina Liver Cancer Drug Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 7.8. MEA
  • 7.8.1. MEA Liver Cancer Drug Market Estimates and Forecasts, By Country, 2018 - 2030 (USD Million)
  • 7.8.2. South Africa
    • 7.8.2.1. Key Country Dynamics
    • 7.8.2.2. Regulatory Framework
    • 7.8.2.3. Competitive Insights
    • 7.8.2.4. South Africa Liver Cancer Drug Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.8.3. Saudi Arabia
    • 7.8.3.1. Key Country Dynamics
    • 7.8.3.2. Regulatory Framework
    • 7.8.3.3. Competitive Insights
    • 7.8.3.4. Saudi Arabia Liver Cancer Drug Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.8.4. UAE
    • 7.8.4.1. Key Country Dynamics
    • 7.8.4.2. Regulatory Framework
    • 7.8.4.3. Competitive Insights
    • 7.8.4.4. UAE Liver Cancer Drug Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.8.5. Kuwait
    • 7.8.5.1. Key Country Dynamics
    • 7.8.5.2. Regulatory Framework
    • 7.8.5.3. Competitive Insights
    • 7.8.5.4. Kuwait Liver Cancer Drug Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 8. Competitive Landscape

• 8.1. Participant Overview
• 8.2. Company Market Position Analysis
• 8.3. Company Categorization
• 8.4. Strategy Mapping
• 8.5. Company Profiles/Listing
  • 8.5.1. Exelixis, Inc.
    • 8.5.1.1. Overview
    • 8.5.1.2. Financial Performance
    • 8.5.1.3. Product Benchmarking
    • 8.5.1.4. Strategic Initiatives
  • 8.5.2. Merck KGaA
    • 8.5.2.1. Overview
    • 8.5.2.2. Financial Performance
    • 8.5.2.3. Product Benchmarking
    • 8.5.2.4. Strategic Initiatives
  • 8.5.3. Eisai Co., Ltd.
    • 8.5.3.1. Overview
    • 8.5.3.2. Financial Performance
    • 8.5.3.3. Product Benchmarking
    • 8.5.3.4. Strategic Initiatives
  • 8.5.4. Bristol-Myers Squibb Company
    • 8.5.4.1. Overview
    • 8.5.4.2. Financial Performance
    • 8.5.4.3. Product Benchmarking
    • 8.5.4.4. Strategic Initiatives
  • 8.5.5. Thermo Fisher Scientific Inc.
    • 8.5.5.1. Overview
    • 8.5.5.2. Financial Performance
    • 8.5.5.3. Product Benchmarking
    • 8.5.5.4. Strategic Initiatives
  • 8.5.6. Pfizer Inc.
    • 8.5.6.1. Overview
    • 8.5.6.2. Financial Performance
    • 8.5.6.3. Product Benchmarking
    • 8.5.6.4. Strategic Initiatives
  • 8.5.7. Eli Lilly and Company
    • 8.5.7.1. Overview
    • 8.5.7.2. Financial Performance
    • 8.5.7.3. Product Benchmarking
    • 8.5.7.4. Strategic Initiatives
  • 8.5.8. F. Hoffmann-La Roche Ltd
    • 8.5.8.1. Overview
    • 8.5.8.2. Financial Performance
    • 8.5.8.3. Product Benchmarking
    • 8.5.8.4. Strategic Initiatives
  • 8.5.9. Novartis AG
    • 8.5.9.1. Overview
    • 8.5.9.2. Financial Performance
    • 8.5.9.3. Product Benchmarking
    • 8.5.9.4. Strategic Initiatives
  • 8.5.10. Bayer AG
    • 8.5.10.1. Overview
    • 8.5.10.2. Financial Performance
    • 8.5.10.3. Product Benchmarking
    • 8.5.10.4. Strategic Initiatives